News

AstraZeneca announces Enhertu combination with pertuzumab granted BTD by FDA
AstraZeneca (AZN) announced Enhertu in combination with pertuzumab has been granted Breakthrough Therapy Designation in the U ...
CURE3d
Enhertu Combo Receives FDA Designation in Metastatic HER2+ Breast Cancer
The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.
Cancer Therapy Advisor28d
De-escalated Neoadjuvant Therapy May Be an Option for HER2+ Early Breast Cancer
Omitting carboplatin from neoadjuvant treatment can improve safety without compromising efficacy in patients with HER2-positive early breast cancer.